Monitor upcoming clinical data readouts in 1H26 for SLE and SSc, and watch for updates on automated manufacturing progress and regulatory pathway discussions with FDA.
Price Chart
Executive Summary
Cabaletta Bio updated its corporate presentation with clinical data showing positive safety and efficacy results from its autoimmune-focused CAR-T therapy rese-cel across multiple trials, including myositis, lupus, and myasthenia gravis, while advancing innovations in preconditioning elimination and automated manufacturing.
Key Facts
- Posted updated corporate presentation with clinical data from RESET trials
- Rese-cel demonstrated favorable safety profile with 95% of patients experiencing no or Grade 1 CRS
- Positive efficacy data in multiple autoimmune conditions including myositis, SLE, and myasthenia gravis
- Advancing innovations in preconditioning elimination and automated manufacturing
- Pivotal myositis study enrolling with planned 2027 BLA submission
Financial Impact
No specific financial figures disclosed in the filing
Risk Factors
- Clinical trial delays
- Regulatory approval risks
- Manufacturing scalability challenges
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759138-26-000016 |
| Document: caba-20260420.htm | 0001759138-26-000016 |
| Document: 0001759138-26-000016-index-headers.html | 0001759138-26-000016 |
| Document: 0001759138-26-000016-index.html | 0001759138-26-000016 |
| Document: 0001759138-26-000016.txt | 0001759138-26-000016 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $2.91 $2.46 | ▼ −15.46% | ▼ −15.57% | $1.91 (−34.36%) |
Aug 15, 2026 6w ago | Institutional Cluster | $2.89 $3.10 | ▲ +7.27% | ▲ +8.46% | $1.91 (−33.91%) |
Aug 13, 2026 7w ago | 8-K | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Aug 13, 2026 7w ago | Press Release | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.01 $2.84 | ▼ −5.65% | ▼ −6.32% | $1.91 (−36.54%) |
Jun 3, 2026 17w ago | 8-K | $3.58 $3.04 | ▼ −15.08% | ▼ −11.26% | $1.91 (−46.65%) |
Jun 1, 2026 17w ago | DEFA14A | $3.67 $3.25 | ▼ −11.44% | ▼ −8.69% | $1.91 (−47.96%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▼ −2.22% | ▼ −2.93% | $1.91 (+47.09%) |
May 14, 2026 20w ago | Press Release | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access